Search Results - Rudi Subirá

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

    Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain by María Teresa Gómez-Casares, Juan Carlos Hernández-Boluda, Antonio Jiménez-Velasco, Joaquin Martínez-López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz, Rudi Subirá

    Published 2017-11-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: